From Diagnosis to Treatment - Part 3 of 4, Diagnosis of Breast Cancer with H&E and Immunohistochemistry Stains
In the case of Breast Cancer, the patient’s cancer is usually detected by a mammogram or palpitation of an experienced Physician. However, these first indications that something is wrong must be confirmed by a more scientific approach. Usually what follows is an actual biopsy; a sample of the tissue in question is removed from the person. Once a tumor is confirmed from the biopsy, then a more radical surgical approach may be necessary or other treatments are performed. Part 3 of the series addresses the importance of proper H&E/ICH sections and staining for diagnosis of breast tumors. A view of optimization and controls for prognostic markers will be examined, and brief overview of IHC diagnosis and treatment will presented.
학습 목표
Discuss the importance of good H&E / IHC sections, and differences in the pathologist’s evaluation of core versus whole-section specimens.
- Understand the differential diagnosis of types of breast tumors.
- To view a good optimization of the antibody as an essential part of laboratory practice.
- Examine a variety of controls for prognostic (graded) IHC markers such as ER/PR/ HER2 .
- A brief overview of the next steps after IHC diagnosis and treatment.
발표자 소개
Dr. Thomas Haas is an attending Pathologist and Director of Molecular Pathology at Mercy Health Systems, Janesville, Wisconsin. He received his Doctor of Osteopathic Medicine from Des Moines University. His daily responsibilities involve anatomic, cytologic, and clinical pathology in a community hospital and system reference laboratory, with participation in tumor board and medical education conferences. His areas of interest include the development of immunohistochemistry panels for tumor diagnosis, molecular pathology, and histotechnology education for the National Society for Histotechnology (NSH). Dr. Haas is board certified in Anatomic and Clinical Pathology.
라이카 바이오시스템즈 Knowledge Pathway 콘텐츠는 에서 이용할 수 있는 라이카 바이오시스템즈 웹사이트 이용 약관의 적용을 받습니다. 법적고지. 라이카 바이오시스템즈 웨비나, 교육 프레젠테이션 및 관련 자료는 특별 주제 관련 일반 정보를 제공하지만 의료, 규정 또는 법률 상담으로 제공되지 않으며 해석되어서는 안 됩니다. 관점과 의견은 발표자/저자의 개인 관점과 의견이며 라이카 바이오시스템즈, 그 직원 또는 대행사의 관점이나 의견을 나타내거나 반영하지 않습니다. 제3자 자원 또는 콘텐츠에 대한 액세스를 제공하는 콘텐츠에 포함된 모든 링크는 오직 편의를 위해 제공됩니다.
모든 제품 사용에 다양한 제품 및 장치의 제품 정보 가이드, 부속 문서 및 작동 설명서를 참조해야 합니다.
Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.